BioMarin Saves Day For La Jolla's Riquent, But All Hangs On Pivotal Trial

With new financing in hand courtesy of BioMarin, La Jolla now hopes to complete its pivotal ASPEN trial for Riquent (abetimus) in lupus nephritis and launch in the U.S. in late 2010